Lux Biosciences, Inc. - Press Releases

	Deutsch
	enlarged text

	Press Releases April 28, 2008 Lux Biosciences’ Presentations at ARVO Highlight Both Topical and Polymer Delivery Technologies Targeting Chronic Inflammatory Ocular Diseases April 24, 2008 Lux Biosciences Reports on Pivotal Programs in Uveitis and Corneal Transplant Rejection at ARVO Meeting February 26, 2008 Lux Biosciences to Provide Update on Four Pipeline Programs, Including Two Phase 3 Clinical Programs, at ARVO February 4, 2008 Lux Biosciences to Present at BIO CEO & Investor Conference 2008 January 30, 2008 Lux Granted Fast Track Designation For LX201 For Corneal Transplant Rejection November 20, 2007 Lux Biosciences to Present at Upcoming Investor Conferences October 29, 2007 Lux Biosciences To Present at Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference September 26, 2007 Lux Biosciences Sponsors October 6 Event to Raise Awareness and Help Fund Research Against Serious Ophthalmic Diseases September 17, 2007 Lux Biosciences to Present at 2007 UBS Global Life Sciences Conference August 30, 2007 Novel Steroid Sparing Strategies for the Treatment of Uveitis and Prevention of Corneal Transplant Rejection to be Subject of International Symposium Sponsored by Lux Biosciences August 7, 2007 Lux Granted Fast Track Designation by FDA for LX211 for The Treatment of Uveitis July 31, 2007 EMEA Committee for Orphan Medicinal Products Recommends Orphan Medicinal Product Designation for Lux Biosciences’ LX 211 for The Treatment of Uveitis June 20, 2007 Lux Biosciences to Present at Jefferies Healthcare Conference May 22, 2007 Lux Biosciences Expands Biomaterials Technology License from Rutgers University for Controlled Ocular Delivery of Pharmaceuticals May 4, 2007 Lux Biosciences’ Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007 April 4, 2007 Lux Biosciences Initiates Clinical Trials of Its Second Pivotal Stage Program March 8, 2007 Lux Biosciences to Present at Cowen & Company 27th Annual Health Care Conference February 20, 2007 Lux Biosciences Initiates LUMINATE Pivotal Clinical Trials of Its Next-Generation Calcineurin Inhibitor, LX211, in Uveitis January 15, 2007 Lux Biosciences Receives Orphan Drug Designation from the FDA For Two Ophthalmic Products November 28, 2006 Lux Biosciences Receives FDA Clearance for LX211 IND November 7, 2006 Lux Biosciences Announces Exclusive Worldwide License Agreement with NIH for Late Stage Ophthalmic Product September 18, 2006 Lux Biosciences Establishes European-Based Operations September 13, 2006 Lux Biosciences Gains Exclusive Worldwide License for Polyarylate Patent Estate from Rutgers University for Ophthalmic Use July 19, 2006 Lux Biosciences Increases Its Series A Venture Financing by $13 Million, Bringing the Total Round to $49 Million; Dr. David Schnell of Prospect Venture Partners Joins Lux Biosciences' Board July 11, 2006 Lux Biosciences Appoints to Board of Directors David Guyer, SVLS Venture Partner and Former CEO of Eyetech May 25, 2006 (2) Isotechnika Signs Agreement Granting Lux Biosciences Worldwide Ophthalmic Rights To ISA247 May 25, 2006 (1) Lux Biosciences Raises $36 Million in Series A Financing and Signs Agreement for Advanced Clinical Stage Product